Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (3) : Bristol Myers Squibb

Bristol Myers Squibb: Enhancing Patient Understanding Through Clear Communication

Bristol Myers Squibb: Enhancing Patient Understanding Through Clear Communication
10/15/2025 | Companies
At Bristol Myers Squibb (BMS), we recognize that how we communicate can be just as impactful as what we communicate — especially when it concerns someone’s health. Patients today face an overwhelming amount of health information — some helpful, some confusing. Whether they’re reading online...
BMS, Bristol Myers Squibb, clinical trial materials, compassionate care, health equity, health information, health literacy, health outcomes, healthcare accessibility, healthcare clarity, informed decisions, medical communication, patient communication, patient empowerment, patient engagement, patient experience, patient trust, patient-centric approach, Universal Patient Language, UPL

Kareem Abdul-Jabbar raises awareness against atrial fibrillation

Kareem Abdul-Jabbar raises awareness against atrial fibrillation
02/24/2023 | Companies
As part of the No Time to Wait campaign, Kareem Abdul-Jabbar is collaborating with Bristol Myers Squibb and Pfizer to raise awareness of atrial fibrillation (AFib) and its symptoms. In support of the campaign, Abdul-Jabbar will talk about his experience with AFib, including what led to his...
AFib, AFib symptoms, atrial fibrillation, Bristol Myers Squibb, campaign, chest pain, collaborating, diagnosis, fatigue, healthcare, irregular heartbeat, Kareem Abdul-Jabbar, light-headedness, No Time to Wait, partnering, Pfizer, racing heart, shortness of breath, symptoms

Power of multiple immunotherapy regimens boost possibility of longer survival

Power of multiple immunotherapy regimens boost possibility of longer survival
01/31/2023 | Companies
A decade ago, the evolution of immuno-oncology altered the therapeutic landscape for patients with a variety of cancers. Although individual immunotherapies have improved patient outcomes, the addition of rational combinations of multiple immunotherapy regimens has resulted in more treatment...
Bristol Myers Squibb, cancers, complementary combinations, CTLA-4, Evolution, immune oncology, immune response, immune system, immunotherapies, immunotherapy combinations, multiple immunotherapy regimens, patient outcomes, patients, PD-1, therapeutic landscape, treatment options


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com